hVIVO (LON:HVO) Insider Purchases £31,200 in Stock

hVIVO plc (LON:HVO) insider Stephen Pinkerton acquired 520,000 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The stock was acquired at an average cost of GBX 6 per share, for a total transaction of £31,200.

hVIVO Stock Performance

LON HVO traded up GBX 1.45 during trading hours on Monday, hitting GBX 6.80. 22,626,840 shares of the company’s stock traded hands, compared to its average volume of 3,340,329. hVIVO plc has a 52 week low of GBX 4.31 and a 52 week high of GBX 22. The firm has a market capitalization of £46.70 million, a P/E ratio of 8.82 and a beta of 0.97. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The business’s fifty day moving average price is GBX 6.26 and its two-hundred day moving average price is GBX 8.75.

hVIVO (LON:HVO) last issued its quarterly earnings data on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. Equities research analysts predict that hVIVO plc will post 1.5492958 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on HVO shares. Shore Capital reduced their price objective on shares of hVIVO from GBX 35 to GBX 25 and set a “buy” rating for the company in a research note on Tuesday, September 23rd. Peel Hunt reaffirmed an “add” rating and issued a GBX 10 target price on shares of hVIVO in a report on Thursday, November 20th. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, hVIVO presently has a consensus rating of “Buy” and an average target price of GBX 17.50.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.